1402569-80-5

Basic information

• Product Name: methyl 3-(benzyloxyamino)-4-(2,4,5-trifluorophenyl) butanoate
• Synonyms: methyl 3-(benzyloxyamino)-4-(2,4,5-trifluorophenyl) butanoate
• CAS NO: 1402569-80-5
• Molecular Weight: 353.341
• Mol File: 1402569-80-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: methyl 3-(benzyloxyamino)-4-(2,4,5-trifluorophenyl) butanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-(benzyloxyamino)-4-(2,4,5-trifluorophenyl) butanoate(1402569-80-5)
• EPA Substance Registry System: methyl 3-(benzyloxyamino)-4-(2,4,5-trifluorophenyl) butanoate(1402569-80-5)

Safety Data

• Hazardous Substances Data: 1402569-80-5(Hazardous Substances Data)

Upstream product

• 1352613-28-5 2,4,5-trifluorobenzene magnesium chloride 
• 367-23-7 1,2,4-trifluorobenzene 
• 1260029-44-4 (E)-4-(2,4,5-trifluoro-phenyl)-but-2-enoic acid methyl ester 
• 2687-43-6 O-benzylhydoxylamine hydrochloride 

Downstream Products

• 767352-29-4 (R)-3-((benzyloxy)amino)-4-(2,4,5-trifluorophenyl)butanoic acid 

Relevant articles and documents

PREPARATION OF SITAGLIPTIN INTERMEDIATES

The invention relates to the preparation of chiral compounds, in particular to the preparation of chiral compounds which may be used as intermediates for the preparation of anti-diabetic agents, preferably sitagliptin.

PREPARATION OF OPTICALLY PURE ?-AMINO ACID TYPE ACTIVE PHARMACEUTICAL INGREDIENTS AND INTERMEDIATES THEREOF

The present invention relates to the preparation of optically resolved chiral compounds of β-amino acid type active pharmaceutical ingredients (API), more specifically to β-aminobutyryl substituted compounds and especially β-aminobutyryl compounds having γ-bound aryl groups. The present invention more particularly relates to the preparation of enantiomerically enriched chiral compounds useful as intermediates for the preparation of anti-diabetic agents, preferably sitagliptin.

Preparation of Sitagliptin Intermediates

The invention relates to the preparation of chiral compounds, in particular to the preparation of chiral compounds which may be used as intermediates for the preparation of anti-diabetic agents, preferably sitagliptin.